A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

Exclusion criteria

• . Evidence of another kidney disease or kidney disease secondary to an infectious process.
• . History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. Patients whose results are compatible with prior immunization or treatment may be included.
• . Body mass index (BMI) \> 42 kg/m2.
• . Significant history or evidence of clinically significant disorder, condition, current illness, or disease that, in the opinion of the Investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion (eg, severe cardiac disease, cardiac conduction defect, or severe or chronic hepatobiliary disease).
• . History of malignancy not in remission within the last 5 years other than adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.
• . History of any organ or bone marrow transplant, including kidney grafts.
• . History of alcoholism or drug/chemical abuse within 12 months.
• . Preplanned surgery or procedures that would interfere with the conduct of the study.

Change in Urine Biomarker: Synaptopodin

Timeframe: Approximately 1 year